Austin, Texas – April 7, 2026 – Saanroo, a global science-driven wellness ingredient company, today announced the publication of a new peer-reviewed clinical study showing that Levagen+ (palmitoylethanolamide, PEA) significantly improved mobility, comfort, and functional outcomes in dogs and cats with joint pain. Published in Frontiers in Veterinary Science, the 6-week randomised, double-blind, placebo-controlled trial evaluated 50 dogs and 50 cats and marks Sannroo’s first published companion animal clinical study of Levagen+.
The publication comes at a time of growing momentum in pet wellness. The global pet supplements market was estimated at USD 2.76 billion in 2025 and is projected to reach USD 4.65 billion by 2033, reflecting rising demand for evidence-based solutions that support long-term quality of life for companion animals. Joint health remains one of the most important concerns in this space, as it helps maintain mobility and ensure a higher quality of life as animals age.
For Saanroo, the study represents a logical next step in Levagen+’s scientific evolution. Levagen+ already has strong clinical backing in human joint health, recovery, and related inflammation-linked applications. Given the high prevalence of joint discomfort and mobility issues in ageing pets, the company saw a clear opportunity to investigate whether the same positive effects observed in humans could also extend to companion animals. The published findings suggest they can.
In dogs, 76% of those receiving Levagen+ were classified as successfully treated, compared to 40% in the placebo group (p < 0.05), with significant improvements observed across multiple pain and functional interference domains. In cats, statistically significant between-group differences were observed in specific functional tasks, including jumping up and jumping down (p < 0.05). Reductions in “pain today” scores were also significant at both week 2 and week 6 (p < 0.05). Levagen+ was well tolerated in both species.
“Joint health is a common and growing concern for pet owners around the world, and because Levagen+ already had strong clinical backing in human joint health, it was only natural to explore whether it could deliver similar benefits in dogs and cats,” said John Quilter, CEO, Saanroo. “This first published companion animal study of Levagen+ is an important milestone for the brand. It shows that the science behind Levagen+ has relevance beyond human health and opens the door to new opportunities in companion animal wellness.”
The study also reinforces the broader potential of PEA as a non-NSAID option in pet health formulations. In the paper’s discussion, the authors note that current management of osteoarthritis and joint pain in companion animals can be limited by adverse effects associated with long-term pharmacologic use, underscoring the need for well-tolerated alternatives that support mobility and daily function.
Levagen+ is a highly bioavailable form of PEA that utilises Pharmako Biotechnologies LipiSperse technology to enhance dispersibility and absorption. Saanroo continues to build its body of published clinical evidence on Levagen+ across multiple health pillars, including joint health, recovery, sleep, cognitive support, female health, stress modulation, and now companion animal health. For formulators and brand leaders, the new publication adds meaningful scientific validation for the use of Levagen+ in next-generation pet mobility and wellness products.
To learn more about Levagen+, its applications, applicable categories, and clinical data, visit Saanroo’s booth at SupplySide Connect #222, or contact info@saanroo.com to schedule a meeting.
